Success with the use of the novel KRAS inhibitor Sotorasib in lung cancer patients and colon cancer patients with cancers harbouring specifically G12C mutant KRAS protein [38,39] has raised hope for similar treatments for PDAC. Here, KRAS is linked to lung carcinoma.